ZYBT Company Profile and Key Details

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) closed at $8.01 USD, gaining $7.31 (1,047.56%) from the previous close of $0.70. The stock is currently mid-range between its 52-week high and low $0.62 and $13.08. With a market capitalization of about $379.60 million, Zhengye Biotechnology Holding Limited is classified as a small-cap and shows lower-than-market volatility (beta ~-2.17). Key stats such as the average daily volume over the past year has been around 100.92 thousand shares, trading with heavier-than-usual volume. Headquartered in Jilin, JI, Zhengye Biotechnology Holding Limited operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Songlin Song, the company employs approximately 269 people and listed since January 07, 2025. Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations.

Zhengye Biotechnology Holding Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.21. This means the shares are trading above this model’s fair value.

Short-term trend indicators are bullishly aligned (SMA20 -11.31%, SMA50 -29.76%, SMA200 -81.77%). The stock’s 14-day RSI is 36.24 (weak momentum), while the ATR of 0.12 points to moderate volatility. The stock remains hovering near 52-week lows, trading -94.34% below its high and over 12.43% above its low. Average 10-day trading volume of 26.36 million shares is significantly above the 3-month average of 2.76 million, indicating heightened recent market interest.

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) shares are flat -4.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Zhengye Biotechnology Holding Limited trading at a premium to the broader market with a P/E of -24.26. Our AI forecast model points to short-term weakness (-91.89% over two weeks), a medium-term fall (-97.5% over three months), and a longer-term loss (-92.38% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Zhengye Biotechnology Holding Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -91.89%, with price expected at $0.65 by July 31, 2026, within a range of $0.60 to $0.71 3-Month Outlook: Projected fall of -97.5%, reaching $0.20 by October 12, 2026, with a range of $0.00 to $0.53. 1-Year Outlook: Projected loss of -92.38%, with price at $0.61 by July 20, 2027, within a range of $0.31 to $0.91.

Zhengye Biotechnology Holding Limited trades at a P/E ratio of -24.26, slightly below the S&P 500 average, with a price-to-sales ratio of 21.4 and a price-to-book ratio of 6.86 trading at moderately above to book value. The P/FCF stands at 43.84, also above market averages.